These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21597260)

  • 1. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
    McDonald GT; Sullivan R; Paré GC; Graham CH
    Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
    Abdul-Ghani R; Serra V; Györffy B; Jürchott K; Solf A; Dietel M; Schäfer R
    Oncogene; 2006 Mar; 25(12):1743-52. PubMed ID: 16288223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
    Xu R; Nakano K; Iwasaki H; Kumagai M; Wakabayashi R; Yamasaki A; Suzuki H; Mibu R; Onishi H; Katano M
    Cancer Lett; 2011 Jul; 306(2):151-60. PubMed ID: 21429662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
    Smolensky D; Rathore K; Cekanova M
    BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.
    Long XH; Zhong ZH; Peng AF; Zhu LB; Wang H; Zhang GM; Liu ZL
    Mol Med Rep; 2014 Dec; 10(6):2967-72. PubMed ID: 25310590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
    Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
    Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.
    Fujiwara Y; Kawada K; Takano D; Tanimura S; Ozaki K; Kohno M
    Biochem Biophys Res Commun; 2006 Feb; 340(2):560-6. PubMed ID: 16378598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin].
    Ai YW; Yu HG; Yu JP; Yang Y; Li H; Hu XW; Luo HS
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):494-7. PubMed ID: 19062713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N; Luo J; Guo X
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the PI3K/AKT pathway reduces tumor necrosis factor-alpha production in the cellular response to wear particles in vitro.
    Huang JB; Ding Y; Huang DS; Liang AJ; Zeng WK; Zeng ZP; Qin CQ; Barden B
    Artif Organs; 2013 Mar; 37(3):298-307. PubMed ID: 23330804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.